Wuhan Ruijian received tens of millions of yuan in Pre-A round financing, the People's Fu Industrial Fund and China Capital co-investment.

Guide: Wuhan Ruijian multi-million financing, is committed to chemically induced adult cell drug developmentWuhan Regen Pharmaceutical Technology Co., Ltd., a leader in the development of chemically induced protoblastatal drugs, announced the completion of tens of millions of yuan in Pre-A round financing!---- This round of financing by the People's Fu Industrial Fund and China Capital co-investment to completeThis round of financing will be used to complete the safety evaluation and IND declaration of NouvNeu001, the first Parkinson's pipeline of Ruijian PharmaceuticalsWuhan Rejian Pharmaceutical Technology Co., Ltdis a new platform cell drug company focused on solving unmet medical needs, using its unique induced small molecular library and live cell real-time reporting platform, completed a number of chemically induced adult cell regeneration cell drug research and development pipeline, covering neurodegenerative diseases, metabolic system diseases, and rare diseases and other fieldsFounded in August 2017 by a returning scholar from the University of Cambridge, The two founders have more than 10 years of successful overseas experience in the development of cell drugs and nucleic acid drugsSince its inception, Wuhan Ruijian has been awarded the National People's Social Administration's "Entrepreneurial Start-up Program for Students", the EPSRC Industrial Innovation Project in the United Kingdom, the "100-person Plan" in Hubei Province, the support of Wuhan City's industry leader and the "3551 Talent Program"; In January 2019, Wuhan Ruijian completed the angel round financing, led by China Capital, Guanggu Talent Fund and investmentAt present, Wuhan Ruijian has completed the GMP-level seed cell bank, more than 100 kinds of induced chemical small molecular library, iPSC/ESC induced differentiation system, and non-stem cell conversion system of the improvement and constructionIts first pipeline, NouvNeu001, achieved excellent therapeutic results in the primate model of Parkinson's disease and completed pilot productionThis round of financing will focus on promoting the safety evaluation of the pipeline and IND declaration, and comprehensively enhance the comprehensive strength and industrialization process of Wuhan Ruijian Pharmaceuticals, at the same time, this round of financing also highlights the emergence of investors on the development of Wuhan Ruijian Pharmaceuticals great confidenceHuafang Capital China Capital is a fund focused on the field of biomedicine investment, focusing on biomedicine, high-end medical equipment, medical services, medical information and other directions, has completed a number of sub-sectors of the head of enterprise investmentThe core members of China Side Capital have been deeply cultivated in the pharmaceutical industry for many years, have a deep understanding and understanding of the pharmaceutical and health industry, and have unique insights into the development trends of the industry, the innovation of the project, the differentiation of the project and the ability of the entrepreneurial team to buildChina's capital through industrial resources to be invested enterprises to help its rapid growthHuafang Capital is also an investor in Wuhan Ruijian Pharmaceutical Angel Wheel, the rapid and steady promotion and development of the Rejian Pharmaceutical Pipeline, demonstrating the team's forward-looking and strong research and development capabilities in innovative therapiesRenfu Industry Fund Renfu Pharmaceuticals, established a professional VC/PE management agency in 2013, initiated the establishment of a number of pharmaceutical industry funds, fully relying on more than a decade of investment in pharmaceutical enterprises and the industrial investor advantages of operating pharmaceutical enterprises, brought together a group of professional investment and research team with rich experience, a wide range of high-quality discovery of valuable "investment targets", export management import resources, help the rapid growth of investment targets, promote the development of key areas of business development, help people to become a competitive international pharmaceutical enterprises